<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="table5" position="float"><label>Table 5.</label><caption><title>Bootstrap estimated seroprevalence for each of the four DENV serotypes and ZIKV adjusted for sampling bias in two cross-sectional surveys conducted in the general population from the Society Islands, French Polynesia, in 2014 and 2015.</title><p>Results from the cross-sectional surveys in the Society Islands, French Polynesia, in 2014 and 2015 show a decline in seroprevalence by MIA against all 4 DENV serotypes and ZIKV. However, the 2014 sample included more individuals that tested positive for&#160;&gt;1 DENV serotype and are assumed to be a higher risk group. We used a bootstrap method with 10,000 iterations which estimated seroprevalence from a sample of the 2014 dataset, taken with replacement, weighted by the exposure distribution to other DENV viruses in the 2015 survey. After adjusting for the sample bias, there was no evidence of a decline in seroprevalence for DENV-1, DENV-3, or DENV-4, which had circulated in the years preceding the 2014 sample collection (<xref ref-type="bibr" rid="bib36">World Health Organisation, 2019</xref>), but there remained strong evidence that ZIKV seroprevalence declined between 2014&#8211;15.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom">Virus</th><th valign="bottom">2014 seroprevalence (95% CI) <break/>(<italic>n</italic>&#160;=&#160;49)</th><th valign="bottom">2014 bootstrap estimates of seroprevalence (95% CI)</th><th valign="bottom">2015 seroprevalence (95% CI) <break/>(<italic>n</italic>&#160;=&#160;700)</th><th valign="bottom"><italic>p</italic>-value<sup>*</sup></th></tr></thead><tbody><tr><td valign="bottom">DENV1</td><td valign="bottom">86 (73&#8211;94)</td><td valign="bottom">74 (61&#8211;86)</td><td valign="bottom">80 (77&#8211;83)</td><td valign="bottom">0.36</td></tr><tr><td valign="bottom">DENV2</td><td valign="bottom">47 (33&#8211;62)</td><td valign="bottom">38 (24&#8211;53)</td><td valign="bottom">18 (15&#8211;21)</td><td valign="bottom">0.0008</td></tr><tr><td valign="bottom">DENV3</td><td valign="bottom">76 (61&#8211;87)</td><td valign="bottom">64 (51&#8211;78)</td><td valign="bottom">55 (51&#8211;59)</td><td valign="bottom">0.21</td></tr><tr><td valign="bottom">DENV4</td><td valign="bottom">63 (48&#8211;77)</td><td valign="bottom">50 (37&#8211;65)</td><td valign="bottom">42 (38&#8211;46)</td><td valign="bottom">0.42</td></tr><tr><td valign="bottom">ZIKV</td><td valign="bottom">37 (23&#8211;52)</td><td valign="bottom">42 (29&#8211;55)</td><td valign="bottom">22 (19&#8211;25)</td><td valign="bottom">0.0047</td></tr></tbody></table><table-wrap-foot><fn><p><sup>*</sup>chi-squared test comparing 2014 bootstrap estimates with 2015 results.</p></fn></table-wrap-foot></table-wrap>